Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

3903 ARTÍCULOS , VIENDO DEL 496 AL 510

An 85-year old male with levodopa-responsive parkinsonism followed by dementia and supranuclear ophthalmoplegia caused by alzheimer-type pathology without Lewy bodies

Kasahata N, Hagiwara M, Kato H, Nakamura A, Uchihara T.

J Alzheimers Dis. 2014;39(3):471-6. doi: 10.3233/JAD-131508.

Drug-induced impulse control disorders: a review

Atmaca M.

Curr Clin Pharmacol. 2014 Feb;9(1):70-4. doi: 10.2174/1574884708666131111202954.

Targeting chelatable iron as a therapeutic modality in Parkinson's disease

Devos D, Moreau C, Devedjian JC, Kluza J, Petrault M, Laloux C, Jonneaux A, Ryckewaert G, Garçon G, Rouaix N, Duhamel A, Jissendi P, Dujardin K, Auger F, Ravasi L, Hopes L, Grolez G, Firdaus W, Sablonnière B, Strubi-Vuillaume I, Zahr N, Destée A, Corvol JC, Pöltl D, Leist M, Rose C, Defebvre L, Marchetti P, Cabantchik ZI, Bordet R.

Antioxid Redox Signal. 2014 Jul 10;21(2):195-210. doi: 10.1089/ars.2013.5593. Epub 2014 Feb 6.

New diagnostic perspectives on obsessive-compulsive personality disorder and its links with other conditions

Starcevic V, Brakoulias V.

Curr Opin Psychiatry. 2014 Jan;27(1):62-7. doi: 10.1097/YCO.0000000000000030.

Promise of pharmacogenomics for drug discovery, treatment and prevention of Parkinson's disease. A perspective

Payami H, Factor SA.

Neurotherapeutics. 2014 Jan;11(1):111-6. doi: 10.1007/s13311-013-0237-y.

Behavioral disorders in Parkinson's disease: the role of dopamine

Antonelli F, Strafella AP.

Parkinsonism Relat Disord. 2014 Jan;20 Suppl 1:S10-2. doi: 10.1016/S1353-8020(13)70005-1.

Predictors of Parkinson's disease dementia: towards targeted therapies for a heterogeneous disease

Moore SF, Barker RA.

Parkinsonism Relat Disord. 2014 Jan;20 Suppl 1:S104-7. doi: 10.1016/S1353-8020(13)70026-9.

Exercise: is it a neuroprotective and if so, how does it work?

Zigmond MJ, Smeyne RJ.

Parkinsonism Relat Disord. 2014 Jan;20 Suppl 1:S123-7. doi: 10.1016/S1353-8020(13)70030-0.

Promises of novel multi-target neuroprotective and neurorestorative drugs for Parkinson's disease

Youdim MB, Kupershmidt L, Amit T, Weinreb O.

Parkinsonism Relat Disord. 2014 Jan;20 Suppl 1:S132-6. doi: 10.1016/S1353-8020(13)70032-4.

Niemann-Pick's and Gaucher's diseases

Stern G.

Parkinsonism Relat Disord. 2014 Jan;20 Suppl 1:S143-6. doi: 10.1016/S1353-8020(13)70034-8.

Investigating FUS variation in Parkinson's disease

Labbé C, Rayaprolu S, Soto-Ortolaza A, Ogaki K, Uitti RJ, Wszolek ZK, Ross OA.

Parkinsonism Relat Disord. 2014 Jan;20 Suppl 1(0 1):S147-9. doi: 10.1016/S1353-8020(13)70035-X.

Stem cell grafting in parkinsonism--why, how and when

de Munter JP, Melamed E, Wolters ECh.

Parkinsonism Relat Disord. 2014 Jan;20 Suppl 1:S150-3. doi: 10.1016/S1353-8020(13)70036-1.

Genetic causes of Parkinson's disease and their links to autophagy regulation

Pan PY, Yue Z.

Parkinsonism Relat Disord. 2014 Jan;20 Suppl 1:S154-7. doi: 10.1016/S1353-8020(13)70037-3.

Role of iron in UPS impairment model of Parkinson's disease

Le W.

Parkinsonism Relat Disord. 2014 Jan;20 Suppl 1:S158-61. doi: 10.1016/S1353-8020(13)70038-5.

How to organize multispecialty care for patients with Parkinson's disease

van der Marck MA, Bloem BR.

Parkinsonism Relat Disord. 2014 Jan;20 Suppl 1:S167-73. doi: 10.1016/S1353-8020(13)70040-3.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias